Skip to main content
. 2019 May 24;10:530. doi: 10.3389/fphar.2019.00530

FIGURE 3.

FIGURE 3

Plasma concentrations of selected tamoxifen metabolites stratified according to CYP2D6 genotype in 117 Iranian breast cancer patients receiving 20 mg/day tamoxifen for at least 4 months. Non-adherent patients with plasma tamoxifen concentrations <100 nM were excluded. The patients who were scheduled for the dose escalation trial are depicted in red. The differences between the genotype groups were assessed by Kruskal–Wallis Test.